LifeMD, Inc. Q4 FY2023 earnings call

Management Statement and Operational Highlights

• 2023 was a record-setting year with revenue, patient subscriber base, and profitability all increasing sharply. The GLP-1 weight management program launched in April 2023 grew to over 22,000 active patients by year-end 2023 and over 35,000 as of the call date.
• Executed a collaboration agreement with Medifast in December 2023, including $10 million in collaboration fees and a $10 million equity investment, validating the strength of LifeMD's telehealth platform.
• Lifestyle Healthcare (RexMD) had double-digit revenue growth for the fourth consecutive year, and WorkSimpli continued strong growth with 50% year-over-year revenue growth and EBITDA margins over 25%.
• In 2024, focus on four key objectives: continuing rapid growth in GLP-1 weight loss market, growing RexMD business, advancing医保 reimbursement for medical services, and maintaining growth and profitability.

Segment Performance

• Weight Management: In 2023, the weight management program finished with over 22,000 active patient subscribers, well ahead of the 20,000 previously guided, and as of the call date, had over 35,000 patients. The revenue contribution from this segment is significant due to its rapid growth.
• Lifestyle Healthcare (led by RexMD): Had fourth consecutive year of double-digit annual revenue growth, with a contribution margin in excess of 30% in 2023.
• WorkSimpli: Continued consistent growth trajectory with 50% year-over-year revenue growth and EBITDA margins exceeding 25%.

Guidance

• Raised consolidated revenue guidance for 2024 to at least $200 million from the previous $195 million to $205 million.
• Reaffirmed adjusted EBITDA guidance for 2024 between $18 million and $22 million.
• Expect to continue rapid growth in GLP-1 weight loss market, advance医保 reimbursement efforts, and aim to make the telehealth business profitable on a standalone basis by the middle of 2024.

Risks

• Market Competition: Intense competition in the telehealth and weight management spaces could impact market share and growth.
• 医保 Reimbursement Delays: Delays in推进医保 reimbursement for medical services could slow down business expansion.
• Drug Pricing Changes: Significant changes in GLP-1 drug pricing, such as generic launches, could affect demand for LifeMD's platform.

Question and Answer

• Q: David Larsen on weight management program, Medifast relationship, onboarding pace, and drug pricing A: Justin Schreiber mentioned they're happy with the Medifast collaboration progress, averaging over 400 new patient acquisitions per day in the last 30 days, and haven't changed pricing, focusing on high-quality care. On generic GLP-1s, the first generic Victoza is coming in June 2024, and LifeMD is well-positioned for generic offerings.
• Q: William Wood on RexMD growth and new offerings A: Justin Schreiber said they're planning to launch an HRT offering under RexMD in the coming months, with opinion leaders involved and aiming for a gold standard in HRT clinically.
• Q: Ilya Zubkov on WorkSimpli offering change and user growth A: Marc Benathen said WorkSimpli has diversified its offering, including resume, legal forms, Sign Simply, and penetrated small businesses, expects user growth to recover in 2024 as economics improve.
• Q: Yi Chen on GLP-1 market share, patient age, and retention A: Marc Benathen said the weight management market is in early stages with massive runway, average patient age in mid-40s, and strong early retention rates, but long-term retention is hard to predict.
• Q: David Larsen on customer acquisition costs and IQVIA agreement A: Marc Benathen said CACs are managed with good return on ad spend, and the agreement with IQVIA is a joint venture exploring pharma opportunities, optimistic about future fruitful relationship.